Leerink Partnrs Brokers Boost Earnings Estimates for Hookipa Pharma Inc (NASDAQ:HOOK)

Hookipa Pharma Inc (NASDAQ:HOOK) – Research analysts at Leerink Partnrs upped their Q2 2024 earnings estimates for Hookipa Pharma in a report issued on Wednesday, July 24th. Leerink Partnrs analyst A. Berens now expects that the company will post earnings of ($1.48) per share for the quarter, up from their previous forecast of ($1.50). The consensus estimate for Hookipa Pharma’s current full-year earnings is ($2.57) per share. Leerink Partnrs also issued estimates for Hookipa Pharma’s Q3 2024 earnings at ($1.03) EPS, Q4 2024 earnings at ($0.27) EPS, FY2024 earnings at ($1.33) EPS, FY2025 earnings at ($1.75) EPS, FY2026 earnings at ($1.57) EPS and FY2027 earnings at ($1.01) EPS.

Hookipa Pharma (NASDAQ:HOOK) last posted its quarterly earnings data on Thursday, May 9th. The company reported $1.20 EPS for the quarter, topping the consensus estimate of ($1.20) by $2.40. The company had revenue of $36.60 million during the quarter, compared to analyst estimates of $3.20 million. Hookipa Pharma had a negative net margin of 88.73% and a negative return on equity of 33.33%. During the same period in the previous year, the firm earned ($2.70) earnings per share.

HOOK has been the subject of several other reports. Royal Bank of Canada reiterated an “outperform” rating and set a $50.00 target price on shares of Hookipa Pharma in a research report on Tuesday, May 21st. JMP Securities decreased their target price on Hookipa Pharma from $50.00 to $23.00 and set a “market outperform” rating for the company in a research report on Friday. Finally, HC Wainwright lifted their target price on Hookipa Pharma from $50.00 to $60.00 and gave the stock a “buy” rating in a research report on Wednesday, June 5th.

Hookipa Pharma Trading Down 2.7 %

NASDAQ:HOOK opened at $6.15 on Friday. Hookipa Pharma has a twelve month low of $4.10 and a twelve month high of $11.30. The company has a market cap of $60.89 million, a price-to-earnings ratio of -1.23 and a beta of 0.81. The stock has a fifty day simple moving average of $7.01 and a 200-day simple moving average of $7.30.

Institutional Trading of Hookipa Pharma

An institutional investor recently bought a new position in Hookipa Pharma stock. Virtu Financial LLC acquired a new stake in Hookipa Pharma Inc (NASDAQ:HOOK) in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 43,021 shares of the company’s stock, valued at approximately $31,000. Institutional investors and hedge funds own 63.88% of the company’s stock.

Hookipa Pharma Company Profile

HOOKIPA Pharma Inc, a clinical-stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase 2 clinical trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors.